MINDERA Trademark

Trademark Overview


On Sunday, November 8, 2020, a trademark application was filed for MINDERA with the United States Patent and Trademark Office. The USPTO has given the MINDERA trademark a serial number of 90305558. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, February 10, 2022. This trademark is owned by MiNDERA Corporation. The MINDERA trademark is filed in the Computer & Software Services & Scientific Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Medical services; Nucleic acid sequencing and analysis services for medical purposes; Genome sequencing and analysis services for medical purposes; Medical genetic analysis and reporting services for diagnostic, prognostic or treatment uses; Medical testing and analysis for diagnostic and treatment purposes; DNA, RNA, nucleic acid and genetic sequencing, screening, and analysis services for medical purposes; Clinical diagnostic and consultation services for medical purposes in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine

Scientific and medical research, namely, analysis of cells, proteins and nucleic acids; Software as a service (SaaS) services and platform as a service (PaaS) featuring computer software platforms using machine-learning algorithms for collecting, storing, analyzing, sharing, reporting, and processing data in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostic research, clinical research, drug development, drug development research, drug efficacy research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine; Hosting an online network service that enables users to store, analyze and share data in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biolog...
mindera

General Information


Serial Number90305558
Word MarkMINDERA
Filing DateSunday, November 8, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, February 10, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Description of MarkThe mark consists of The word Mindera with a line forming a circle shape starting, but not touching, above the d going to the left and down and ending, but not touching, under the d.
Goods and ServicesMedical services; Nucleic acid sequencing and analysis services for medical purposes; Genome sequencing and analysis services for medical purposes; Medical genetic analysis and reporting services for diagnostic, prognostic or treatment uses; Medical testing and analysis for diagnostic and treatment purposes; DNA, RNA, nucleic acid and genetic sequencing, screening, and analysis services for medical purposes; Clinical diagnostic and consultation services for medical purposes in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine
Goods and ServicesScientific and medical research, namely, analysis of cells, proteins and nucleic acids; Software as a service (SaaS) services and platform as a service (PaaS) featuring computer software platforms using machine-learning algorithms for collecting, storing, analyzing, sharing, reporting, and processing data in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostic research, clinical research, drug development, drug development research, drug efficacy research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine; Hosting an online network service that enables users to store, analyze and share data in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine; Clinical diagnostic and consultation services for research purposes in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine; Computer services, namely, cloud hosting provider services and onsite provider services in the nature of technical support services, namely, installation, administration, and troubleshooting of problems for computer software for storing, analyzing and sharing information in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine; Providing an online network service that enables users to store, access, manage, analyze and share data for use in the fields of nucleic acid sequencing, genotyping, medical diagnostics, clinical diagnostics, medical research, diagnostics, clinical research, drug development, drug development research, medical laboratory research, life sciences, biology, microbiology, immunology, metagenomics, genetic testing, genetics, oncology, dermatology, and personalized medicine; Database design and development; RNA analysis services for scientific research purposes involving the identification and treatment of disease; Medical research services

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 8, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, January 8, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMiNDERA Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92123

Trademark Events


Event DateEvent Description
Thursday, February 10, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, February 10, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Friday, July 30, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 30, 2021NON-FINAL ACTION E-MAILED
Friday, July 30, 2021NON-FINAL ACTION WRITTEN
Friday, July 2, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 1, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, July 1, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, April 21, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, April 21, 2021NON-FINAL ACTION E-MAILED
Wednesday, April 21, 2021NON-FINAL ACTION WRITTEN
Wednesday, April 14, 2021ASSIGNED TO EXAMINER
Saturday, January 9, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, January 8, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Wednesday, November 11, 2020NEW APPLICATION ENTERED IN TRAM